'Boring' Bodes Well For Future Of Intercept's Ocaliva
This article was originally published in Scrip
Executive Summary
There was nothing to be shocked about in the FDA's briefing documents released ahead of its April 7 meeting of its Gastrointestinal Drugs Advisory Committee (GDAC) for Intercept Pharmaceuticals Inc.'s obeticholic acid (OCA), a new molecular entity the company is seeking to market as Ocaliva to treat primary biliary cirrhosis (PBC), a rare and potentially fatal liver disease.